drugset / Trial / NCT00482976

Effect of LY333531 on Vascular and Neural Functions

NCT00482976 ↗

Phase 2 Completed 30 enrolled Chromaderm, Inc. Joslin Diabetes Center · collab
RandomizedCrossoverDouble-blindTreatment

Summary

To determine if protein kinase C beta plays a significant role in vascular endothelial dysfunction, small fiber neural dysfunction, and oxidative stress associated with diabetes mellitus.

Timeline

Start
2003-12
Primary completion
—
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruboxistaurin Small molecule 32 mg —